Schafer Joshua 4
4 · ZEVRA THERAPEUTICS, INC. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Zevra Therapeutics CCO Joshua Schafer Sells 10,500 Shares
What Happened
- Joshua Schafer, Chief Commercial Officer of Zevra Therapeutics (ZVRA), sold 10,500 shares on 2026-02-03. The weighted-average sale price was $9.19 per share, for a total value of roughly $96,500. This was a sale (S) reported as open-market/private sale activity.
Key Details
- Transaction date: 2026-02-03.
- Price: weighted average $9.19; individual trade prices ranged from $8.92 to $9.55 (multiple trades; reporting person can provide detailed breakdown on request).
- Shares sold: 10,500; approximate proceeds: $96,500.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnotes: transaction executed under a 10b5-1 trading plan adopted 3/27/2025 (F1). Reporting person offered to supply full trade-by-trade details if requested (F2).
- Timeliness: filing shows reporting date 2026-02-04 for a 2026-02-03 transaction; no late-filing indication in the provided data.
Context
- This was a sale, which is often routine and may be executed under pre-arranged 10b5-1 plans; it is not, by itself, evidence of company performance. No options were exercised and no awards or gifts were involved.
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
[F1][F2]2026-02-03$9.19/sh−10,500$96,500→ 62,278 total
Footnotes (2)
- [F1]Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $8.92 to $9.55. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Signature
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Joshua Schafer|2026-02-04